Loxo Oncology
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Loxo Oncology sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Loxo Oncology: 14 sponsored US clinical trials, 2 recruiting.
Loxo Oncology sponsors 14 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 6 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Small Lymphocytic Lymphoma, with 5 trials.
Top-decile sponsor footprint
Loxo Oncology ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
14 total, page 1 of 1
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants
NCT05176314
A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
NCT05136404
A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants
NCT05089019
A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
NCT04782076
Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants
NCT05134337
Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants
NCT05134350
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
NCT03740529
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 1 |
| Phase 3 | 6 |
What is open in the Loxo Oncology pipeline
2 recruiting of 14 indexed (14% open); 7 completed (50%).
Phase mix: 6 late (III/IV) vs 8 early (I/II) (balanced across stages).
Top condition: Small Lymphocytic Lymphoma (5 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Loxo Oncology: open-pipeline peers nationwide
Peers matched on 14 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Loxo Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 trials (± recruiting share)
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Loxo Oncology page
14 registered trials is a research-attention snapshot, not an endorsement of Loxo Oncology or any single study.
- 2 of Loxo Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Small Lymphocytic Lymphoma is the condition Loxo Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Small Lymphocytic Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Loxo Oncology pipeline card: 14 registered trials from official public datasets.Report a data error.